Complicated skin and skin-structure infections and catheter-related bloodstream infections: Noninferiority of linezolid in a phase 3 study

Clinical Infectious Diseases

Volumn 48, Issue 2, 2009, Pages 203-212

  Wilcox, Mark H ^a   Tack, Kenneth J ^d,h   Bouza, Emilio ^b   Herr, Daniel L ^e   Ruf, Bernhard R ^c   Ijzerman, M Marian ^d,i   Croos Dabrera, Rodney V ^d   Kunkel, Mark J ^f   Knirsch, Charles ^d,g  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d PFIZER INC   (United States)

^e WASHINGTON HOSPITAL CENTER   (United States)

^f Pfizer Medical   (United States)

^g Pf Izer Global Research and Development   (United States)

^h Private Consultancy   (United States)

ⁱ NanoBio Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOXACILLIN; LINEZOLID; OXACILLIN; VANCOMYCIN; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; ANEMIA; ANTIBIOTIC THERAPY; ARTERY CATHETER; ARTICLE; BACTERIUM CULTURE; BLURRED VISION; BONE MARROW SUPPRESSION; CATHETER INFECTION; CATHETERIZATION; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG FEVER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; LACTIC ACIDOSIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PULMONARY ARTERY CATHETER; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SKIN INFECTION; SKIN STRUCTURE; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING; AGED; BACTEREMIA; BACTERIAL SKIN DISEASE; CROSS INFECTION; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; MIDDLE AGED;

ACETAMIDES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; CATHETER-RELATED INFECTIONS; CROSS INFECTION; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES; SKIN DISEASES, BACTERIAL; VANCOMYCIN;

EID: 58749115917     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/595686     Document Type: Article

References (33)

1. Edwards JR, Peterson KD, Andrus ML, et al. National Healthcare Safety Network (NHSN) Report, data summary for 2006, issued June 2007. Am J Infect Control 2007; 35:290-301.
2. Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. Mayo Clin Proc 2006; 81:1159-71.
3. Laupland KB, Lee H, Gregson DB, Manns BJ. Cost of intensive care unit-acquired bloodstream infections. J Hosp Infect 2006; 63:124-32.
4. Orsi GB, Di Stefano L, Noah N. Hospital-acquired, laboratory-confirmed bloodstream infection: increased hospital stay and direct costs. Infect Control Hosp Epidemiol 2002; 23:190-7.
5. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality. JAMA 1994; 271:1598-601.
6. Renaud B, Brun-Buisson C. Outcomes of primary and catheter-related bacteremia: a cohort and case-control study in critically ill patients. Am J Respir Crit Care Med 2001; 163:1584-90.
7. Blot SI, Depuydt P, Annemans L, et al. Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections. Clin Infect Dis 2005; 41:1591-8.
8. DiGiovine B, Chenoweth C, Watts C, Higgins M. The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. Am J Respir Crit Care Med 1999; 160:976-81.
9. Dimick JB, Pelz RK, Consunji R, Swoboda SM, Hendrix CW, Lipsett PA. Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit. Arch Surg 2001; 136:229-34.
10. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001; 32:1249-72.
11. Raad I, Bompart F, Hachem R. Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia. Eur J Clin Microbiol Infect Dis 1999; 18:199-202.
12. Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005; 40:374-80.
13. Henkel T. Catheter-related blood stream infection: a phase 2 randomized, controlled trial: dalbavancin vs. vancomycin. 15 April 2004. Available at: http://www.fda.gov/cder/drug/antimicrobial/FDAIDSAISAPPresentations/ CRBSI15Apr04v2-revised.ppt. Accessed 2 October 2007.
14. Draghi DC, Sheehan DJ, Hogan P, Sahm DF. In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program. Antimicrob Agents Chemother 2005; 49:5024-32.
15. Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000; 44:3408-13.
16. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34:1481-90.
17. Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 2006; 42:597-607.
18. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32:402-12.
19. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003; 25:980-92.
20. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 2005; 56:923-9.
21. Tack K, Wilcox M, Bouza E, et al. Linezolid vs. vancomycin or oxacillin/dicloxacillin for the treatment of catheter-related bloodstream infections (CRSBI) [abstract K-1748]. In: Program and abstracts of the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2007.
22. Pfizer. Linezolid vs vancomycin/oxacillin/dicloxacillin in the treatment of catheter-related gram-positive bloodstream infections. Protocol M12600080. PhRMA Web Synopsis. 8 June 2007. Available at: http://pdf. clinicalstudyresults.org/documents/company-study-1480-0.pdf. Accessed 12 September 2007.
23. Lemeshow S, Teres D, Klar J, Avrunin JS, Gehlbach SH, Rapoport J. Mortality Probability Models (MPM II) based on an international cohort of intensive care unit patients. JAMA 1993; 270:2478-86.
24. US Food and Drug Administration/Center for Drug Evaluation and Research. Guidance for industry catheter-related bloodstream infections: developing antimicrobial drugs for treatment: US Department of Health and Human Services Food and Drug Administration. 1999. Available at: http://www.fda.gov/ cder/Guidance/3385dft.htm. Accessed 19 August 2007.
25. Brun-Buisson C, Abrouk F, Legrand P, Huet Y, Larabi S, Rapin M. Diagnosis of central venous catheter-related sepsis: critical level of quantitative tip cultures. Arch Intern Med 1987; 147:873-7.
26. Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter: a randomized, controlled trial. Ann Intern Med 1997; 127:257-66.
27. Knirsch C. Issues in conduct of catheter related (CRI) studies. Food and Drug Administration. In: Proceedings of the Anti-Infective Drugs Advisory Committee Meeting. 14 October 2004. Available at: http://www.fda.gov/ OHRMS/DOCKETS/ac/04/slides/2004-4077s1.htm. Accessed 21 August 2007.
28. Wilcox M, Nathwani D, Dryden M. Linezolid compared with teicoplanin for the treatment of suspected or proven gram-positive infections. J Antimicrob Chemother 2004; 53:335-44.
29. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008;8:53-66.
30. Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 2007; 27:1189-97.
31. Gorbach SL, Bartlett JG, Blacklow NR. Infectious diseases. 2nd ed. Philadelphia, PA: WB Saunders, 1998.
32. Mandell GL, Bennett JE, Dolin R. Principles and practice of infectious diseases. 5th ed. New York, NY: Churchill Livingstone, 1999.
33. Bauer LA. Clinical pharmacokinetics and pharmacodynamics. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. 6th ed. New York, NY: McGraw-Hill, 2005:51-73.